Cellectis CLLS 深 沪
交易中 07-25 11:37:07 美东时间
2.5491
+0.549
+27.46%
华盛通- 最 高2.59
- 今 开2.27
- 成交量 52.75万股
- 最 低 2.27
- 昨 收 2.00
- 总市值 2.55亿
- 52周最高 2.59
- 市盈率 静 --
- 换手率 0.53%
- 52周最低 1.10
- 委 比 -98.02%
- 总股本 10000.00万
- 历史最高 50.00
- 量 比 7.09
- 振 幅 16.00%
- 历史最低 0.9628
- 每 手 1
- 风险率 0.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cellectis files $200M mixed shelf offering
Cellectis S.A. (NASDAQ:CLLS) may offer up to $200M in securities over time. Securities may include ordinary shares, American depositary shares, preferred shares, and warrants. Source: SEC filing More ...
07-03 04:31
Cellectis S.A. Announces Board Changes and Strategic Appointments
Cellectis SA ( ($CLLS) ) just unveiled an update. On June 26, 2025, Cellectis S...
06-27 05:01
Cellectis Announces Board Changes Following Shareholders’ Meeting
Cellectis SA ( ($CLLS) ) has provided an update. On June 26, 2025, Cellectis he...
06-27 05:01
Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025
Cellectis held its 2025 Annual General Meeting on June 26, with 57% of voting rights exercised. Resolutions 1-23 and 25-26 were adopted, while resolution 24 was rejected. Mr. André Muller was appointed to the Board of Directors, while Mr. Pierre Bastid and Mr. Axel-Sven Malkomes stepped down. Mr. Muller, currently CEO of Idorsia Pharmaceuticals, brings extensive experience in biotech and finance. For more details, visit Cellectis’ website.
06-26 20:30
Monthly information on share capital and company voting rights
On June 5, 2025, Cellectis provided an update on its shareholding structure as of May 31, 2025. The company reported a total of 100,325,229 shares in its capital and 89,110,384 voting rights. The information is available in the attached document "Voting_Rights_PR_May_2025_EN." Media and investor relations contacts are provided for further inquiries.
06-05 20:30
美股大行评级 | 潜在涨幅158.9%！蒙特利尔银行上调Disc Medicine目标价至120美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1129333511617925121.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 蒙特利尔银行：维持Disc Medicine(IRON)"跑赢大市"评级，目标价从112美元升至120美元</p> <p>• 巴克莱：维持Karyopharm Therapeutics(KPTI)"超配"评级，目标价从5美
05-14 08:48
Barclays Maintains Overweight on Cellectis, Lowers Price Target to $4
Barclays analyst Gena Wang maintains Cellectis (NASDAQ:CLLS) with a Overweight and lowers the price target from $5 to $4.
05-13 22:20
Cellectis Q1 Adj. EPS $(0.17) Beats $(0.23) Estimate, Sales $12.03M Miss $14.61M Estimate
Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.23) by 26.09 percent. This is a 21.43 percent decrease over losses of $(0.14) per share from the
05-13 04:32
Earnings Scheduled For May 12, 2025
Companies Reporting Before The Bell • Superior Industries Intl (NYSE:SUP) is pr...
05-12 16:32
Cellectis Unveils Gene Editing Innovations at ASGCT Meeting
Cellectis SA ( ($CLLS) ) just unveiled an update. On April 28, 2025, Cellectis ...
04-29 04:57
